SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?


To: Arthur Radley who wrote (474)12/12/2003 11:50:37 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 631
 
"We had limited expectations for HuMax-CD4 for psoriasis, and compared to the small amount of money we spent, it was worth finding out if it would be of any value," Genmab CEO Lisa Drakeman told Reuters."Our primary hope for HuMax-CD4 is still cancer."

biz.yahoo.com

Huh? Cancer?

Geeeeeeeeeeez, this company ticks me off. Shotgun pipeline, IMO to get the investment bucks. The alternative is that management can't tell garbage projects from real ones. Take your choice.